Efficacy and safety of metreleptin therapy in patients with type 1 diabetes

A pilot study

Chandna Vasandani, Gregory O. Clark, Beverley Adams-Huet, Claudia Quittner, Abhimanyu Garg

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OBJECTIVE: To study the efficacy and safety of metreleptin therapy in patients with suboptimally controlled type 1 diabetes mellitus (T1DM). RESEARCH DESIGN AND METHODS: After a baseline period of 4 weeks, five female and three male patients with T1DM (mean age 33 years, BMI 23.8 kg/m2) received metreleptin (0.08 mg/kg/day in females and 0.04 mg/kg/day in males) subcutaneously twice daily for 20 weeks followed by an off-therapy period of 4 weeks. RESULTS: Metreleptin therapy did not lower HbA1c significantly compared with the baseline value (mean difference20.19% [22.0 mmol/mol] and 20.04% [20.5 mmol/mol] at 12 and 20 weeks, respectively). Mean body weight reduced significantly by 2.6 and 4.7 kg (P = 0.003) and daily insulin dose by 12.6% and 15.0% at week 12 and 20 (P = 0.006), respectively. CONCLUSIONS: Metreleptin is safe but may not be efficacious in improving glycemic control in patients with T1DM, although it reduces body weight and daily insulin dose modestly.

Original languageEnglish (US)
Pages (from-to)694-697
Number of pages4
JournalDiabetes Care
Volume40
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Type 1 Diabetes Mellitus
Safety
Body Weight
Insulin
Therapeutics
Research Design
metreleptin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Efficacy and safety of metreleptin therapy in patients with type 1 diabetes : A pilot study. / Vasandani, Chandna; Clark, Gregory O.; Adams-Huet, Beverley; Quittner, Claudia; Garg, Abhimanyu.

In: Diabetes Care, Vol. 40, No. 5, 01.05.2017, p. 694-697.

Research output: Contribution to journalArticle

Vasandani, Chandna ; Clark, Gregory O. ; Adams-Huet, Beverley ; Quittner, Claudia ; Garg, Abhimanyu. / Efficacy and safety of metreleptin therapy in patients with type 1 diabetes : A pilot study. In: Diabetes Care. 2017 ; Vol. 40, No. 5. pp. 694-697.
@article{c72383275627466b833c1918c64b457f,
title = "Efficacy and safety of metreleptin therapy in patients with type 1 diabetes: A pilot study",
abstract = "OBJECTIVE: To study the efficacy and safety of metreleptin therapy in patients with suboptimally controlled type 1 diabetes mellitus (T1DM). RESEARCH DESIGN AND METHODS: After a baseline period of 4 weeks, five female and three male patients with T1DM (mean age 33 years, BMI 23.8 kg/m2) received metreleptin (0.08 mg/kg/day in females and 0.04 mg/kg/day in males) subcutaneously twice daily for 20 weeks followed by an off-therapy period of 4 weeks. RESULTS: Metreleptin therapy did not lower HbA1c significantly compared with the baseline value (mean difference20.19{\%} [22.0 mmol/mol] and 20.04{\%} [20.5 mmol/mol] at 12 and 20 weeks, respectively). Mean body weight reduced significantly by 2.6 and 4.7 kg (P = 0.003) and daily insulin dose by 12.6{\%} and 15.0{\%} at week 12 and 20 (P = 0.006), respectively. CONCLUSIONS: Metreleptin is safe but may not be efficacious in improving glycemic control in patients with T1DM, although it reduces body weight and daily insulin dose modestly.",
author = "Chandna Vasandani and Clark, {Gregory O.} and Beverley Adams-Huet and Claudia Quittner and Abhimanyu Garg",
year = "2017",
month = "5",
day = "1",
doi = "10.2337/dc16-1553",
language = "English (US)",
volume = "40",
pages = "694--697",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Efficacy and safety of metreleptin therapy in patients with type 1 diabetes

T2 - A pilot study

AU - Vasandani, Chandna

AU - Clark, Gregory O.

AU - Adams-Huet, Beverley

AU - Quittner, Claudia

AU - Garg, Abhimanyu

PY - 2017/5/1

Y1 - 2017/5/1

N2 - OBJECTIVE: To study the efficacy and safety of metreleptin therapy in patients with suboptimally controlled type 1 diabetes mellitus (T1DM). RESEARCH DESIGN AND METHODS: After a baseline period of 4 weeks, five female and three male patients with T1DM (mean age 33 years, BMI 23.8 kg/m2) received metreleptin (0.08 mg/kg/day in females and 0.04 mg/kg/day in males) subcutaneously twice daily for 20 weeks followed by an off-therapy period of 4 weeks. RESULTS: Metreleptin therapy did not lower HbA1c significantly compared with the baseline value (mean difference20.19% [22.0 mmol/mol] and 20.04% [20.5 mmol/mol] at 12 and 20 weeks, respectively). Mean body weight reduced significantly by 2.6 and 4.7 kg (P = 0.003) and daily insulin dose by 12.6% and 15.0% at week 12 and 20 (P = 0.006), respectively. CONCLUSIONS: Metreleptin is safe but may not be efficacious in improving glycemic control in patients with T1DM, although it reduces body weight and daily insulin dose modestly.

AB - OBJECTIVE: To study the efficacy and safety of metreleptin therapy in patients with suboptimally controlled type 1 diabetes mellitus (T1DM). RESEARCH DESIGN AND METHODS: After a baseline period of 4 weeks, five female and three male patients with T1DM (mean age 33 years, BMI 23.8 kg/m2) received metreleptin (0.08 mg/kg/day in females and 0.04 mg/kg/day in males) subcutaneously twice daily for 20 weeks followed by an off-therapy period of 4 weeks. RESULTS: Metreleptin therapy did not lower HbA1c significantly compared with the baseline value (mean difference20.19% [22.0 mmol/mol] and 20.04% [20.5 mmol/mol] at 12 and 20 weeks, respectively). Mean body weight reduced significantly by 2.6 and 4.7 kg (P = 0.003) and daily insulin dose by 12.6% and 15.0% at week 12 and 20 (P = 0.006), respectively. CONCLUSIONS: Metreleptin is safe but may not be efficacious in improving glycemic control in patients with T1DM, although it reduces body weight and daily insulin dose modestly.

UR - http://www.scopus.com/inward/record.url?scp=85019358405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019358405&partnerID=8YFLogxK

U2 - 10.2337/dc16-1553

DO - 10.2337/dc16-1553

M3 - Article

VL - 40

SP - 694

EP - 697

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -